Remove 2020 Remove Clinical Development Remove Drugs
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent).

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies. My focus has always been on advancing novel medicines from research to clinical development. Over the years, Ive had the privilege of working on more than 25 different products, Bock shared.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors

The Pharma Data

Food and Drug Administration (FDA). The collaboration between Autolus and AGC Biologics began in 2020, with AGC’s Milan facility entrusted with the development, manufacturing, and commercial supply of lentiviral vectors, a critical component in the production of Autolus’ obe-cel CAR-T product.

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

Drug development is a complex and highly regulated process. Before a therapy can be approved for patient use, it must undergo extensive clinical testing and strictly adhere to regulatory guidelines. One of the most significant challenges in drug development is global regulatory variability.

article thumbnail

Why smarter financial planning could be key to clinical trial success

Drug Target Review

Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

SciePro via Getty Images Dive Brief: The Food and Drug Administration has approved a new oral medication for an uncommon kind of tumor, clearing Nuvation Bio’s Ibtrozi on Wednesday for certain people whose metastatic non-small cell lung cancer has a type of alteration in the gene ROS1. though the drug’s commercial prospects are unclear.

FDA
article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Clinical Trials: Pritelivir is currently in phase II clinical trials, with ongoing research into its effectiveness and safety.